Notice of Full Year Results

RNS Number : 9554T

MaxCyte, Inc.

26 March 2019

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Full Year Results

Gaithersburg, Maryland - 26 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, will be announcing its full year audited results for the year ended 31 December 2018 on Wednesday, 24 April 2019.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call and webcast for analysts at 11.00am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.

During the presentation the Company is expected to confirm strong financial progress over the 2018 period, as outlined in the recent trading update; to provide an overview of the Company's novel and proprietary CARMA cell therapy platform in immuno-oncology and the clinical study, which is now underway, of its first wholly-owned lead CAR therapeutic candidate, MCY-M11; and, to highlight key commercial-stage license agreements with leading biotech companies including Kite Pharma, CRISPR Therapeutics and Precision BioSciences.  

About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies. The Company now has more than 70 partnered program licenses in cell therapy with more than 35 licensed for clinical use, including four announced commercial licenses covering potentially more than 30 products with aggregate potential milestones of more than $250M. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

For further information, please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer	[phone]
Nominated Adviser and Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns	[phone]
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji	[phone] [e-mail]

 

END

 

 

NORJAMTTMBJTTBL